Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

72.77EUR
9:32am EDT
Change (% chg)

€0.93 (+1.29%)
Prev Close
€71.84
Open
€71.95
Day's High
€72.88
Day's Low
€71.95
Volume
1,057,539
Avg. Vol
2,734,135
52-wk High
€86.39
52-wk Low
€62.88

Select another date:

Mon, Jul 9 2018

Photo

Sanofi halts production at Pyrenees plant after pollution complaint

PARIS Drugmaker Sanofi has stopped production at a plant in the French Pyrenees after an environment body filed a complaint against what it said was massive air pollution.

UPDATE 1-Sanofi halts production at Pyrenees plant after pollution complaint

* Complaint lodged by France Nature Environnement (Recasts on production being halted)

REFILE-UPDATE 2-Sanofi beefs up diabetes pipeline to retrieve success

* Demand on the rise in spite of pricing pressure, competition

Sanofi beefing up diabetes pipeline to restore growth - executive

PARIS, July 3 Sanofi sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance, a company executive said on Tuesday.

Latecomer Sanofi looks to catch next wave of cancer therapies

PARIS Sanofi missed the boat on immune system-boosting cancer drugs. Now it's trying to catch up.

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

PARIS French drugmaker Sanofi announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA who had helped oversee a revival in PSA's fortunes.

UPDATE 1-Sanofi poaches former PSA finance boss Chasseloup de Chatillon

* Sanofi has been on takeover trail of late (Adds detail, background)

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

PARIS, June 19 French drugmaker Sanofi announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA, to take up a similar position within Sanofi.

Study confirms higher risk of dengue in kids who got Sanofi vaccine

CHICAGO An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus.

Study confirms higher risk of dengue in kids who got Sanofi vaccine

CHICAGO, June 13 An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus.

Select another date: